In conclusion, ESR1 amplifications and MAP3K mutations are novel genomic alterations that are selected upon adjuvant ETs in patients with advanced HR+ HER2- BC, and which represent promising targets of pharmacologic inhibition to reverse acquired tumor resistance. This evidence concerns the gene ESR1 and neoplasm.